| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies |
|
Medicine details |
|
| Medicine name | tucatinib (Tukysa®) |
| Formulation | 50 mg and 150 mg film-coated tablet |
| Reference number | 4569 |
| Indication | In combination with trastuzumab and capecitabine for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 2 prior anti-HER2 treatment regimens |
| Company | Seattle Inc |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/05/2021 |
| NICE guidance | |